Discussion
postoperative pain, lower pain, femoral nerve block, pain, knee arthroplasty, TKA, chronic pain
CHRONIC PAIN, ADVERSE EFFECTS
The objective of this study was to assess the impact of three different doses of topical dexmedetomidine (0.25 μg/kg, 0.5 μg/kg, and 1 μg/kg) in conjunction with H-FICB on acute pain management and the incidence of chronic pain in patients undergoing total knee arthroplasty. The study findings indicated that all three treatment groups demonstrated efficacy and tolerability, with few systemic serious adverse effects. Notably, patients administered with a dosage of 1 μg/kg dexmedetomidine displayed the lowest average postoperative NRS scores and the lowest average LANSS scores throughout the first to sixth postoperative months.Our results showed that this combination technique provided effective postoperative pain control, with lower pain scores and reduced postoperative opioid consumption compared to the control group receiving local anesthetic alone [Dexmedetomidine is a highly selective α
Chronic pain after total knee arthroplasty (TKA) refers to persistent pain lasting more than three months post-surgery that poses a challenge for management and relief [
Based on our research, it appears that the H-FICB technique offers a more comprehensive and effective approach to regional anesthesia for knee joint procedures when compared to other methods like femoral nerve block or adductor canal block [